Compare BLX & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | IMNM |
|---|---|---|
| Founded | 1977 | 2006 |
| Country | Panama | United States |
| Employees | 322 | 168 |
| Industry | Commercial Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | BLX | IMNM |
|---|---|---|
| Price | $43.11 | $19.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $31.44 |
| AVG Volume (30 Days) | 139.8K | ★ 3.1M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 5.67% | N/A |
| EPS Growth | ★ 9.67 | N/A |
| EPS | ★ 6.00 | N/A |
| Revenue | ★ $308,426,000.00 | $9,679,000.00 |
| Revenue This Year | $18.35 | N/A |
| Revenue Next Year | $6.56 | $11.53 |
| P/E Ratio | $7.34 | ★ N/A |
| Revenue Growth | ★ 10.24 | N/A |
| 52 Week Low | $31.14 | $5.15 |
| 52 Week High | $48.38 | $25.30 |
| Indicator | BLX | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 36.68 | 46.91 |
| Support Level | $43.60 | $21.00 |
| Resistance Level | $44.73 | $21.67 |
| Average True Range (ATR) | 0.78 | 1.20 |
| MACD | -0.09 | -0.37 |
| Stochastic Oscillator | 2.56 | 7.93 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.